Cytosar-U, Cytarabine Wire
Comprehensive News Feed for Cytosar-U, Cytarabine (generic).
Results 1 - 20 of 89 in Cytosar-U, Cytarabine (generic)
-
New report: Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Patient outcomes for both diseases remain poor, particularly for elderly and high-risk patients. Comment?
-
Ambit Biosciences Corporation Announces Two Poster Presentations Characterizing The Effects of AC220
Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology in New Orleans. Comment?
-
Combination Therapy With Midostaurin Improves Survival Of AML Patients With FLT3 Mutations, Phase 1
A targeted drug that is active against acute myeloid leukemia is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's annual meeting on Monday, Dec. Comment?
-
Genzyme's Mozobil Shows Promise in Chemosensitization
Dec 8, 2009 - Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow. Comment?
-
Combination therapy with midostaurin improves survival of AML patients with FLT3 mutations, phase 1
A targeted drug that is active against acute myeloid leukemia is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's annual meeting on Monday, Dec. Comment?
-
Combination Therapy With Midostaurin Improves Survival Of AML Patients With FLT3 Mutations
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Genetics ; Conferences ; Clinical Trials / Drug Trials Article Date: 08 Dec 2009 - 0:00 PST A targeted drug that is active against acute myeloid leukemia is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at ... Comment?
-
Celator Pharmaceuticals Presents Interim Data From Phase 2...
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 Liposome Injection versus conventional cytarabine and daunorubicin therapy in patients 60-75 years of age with untreated acute myeloid leukemia were presented at the 51st American Society of ... Comment?
-
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study...
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Celator Pharmaceuticals announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 Liposome Injection versus conventional cytarabine and daunorubicin therapy in patients 60-75 years of ... Comment?
-
Positive Phase II Clinical Data For Clavis Pharma's Elacytarabine Presented At ASH Annual Meeting
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Cancer / Oncology Clavis Pharma ASA announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia was presented at the 51st American Society of Hematology Annual Meeting in New ... Comment?
-
Norwegian Clavis Pharma presents phase II data for AML drug
The event, the 51st American Society of Hematology Annual Meeting was held in New Orleans, Louisiana, USA. Comment?
-
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 Liposome Injection versus conventional cytarabine and daunorubicin therapy in patients 60-75 years of age with untreated acute myeloid leukemia were presented at the 51st American Society of ... Comment?
-
AS1413 regimen yields high response rate and durable responses in...
London, UK, Cambridge, MA, and New Orleans, LA: 7 December 2009 -Antisoma plc announces that positive final data from a phase II trial of AS1413 in patients with secondary acute myeloid leukaemia were presented this weekend at the American Society of Hematology meeting in New Orleans. Comment?
-
Research and Markets: Philippines Pharmaceuticals and Healthcare...
Research and Markets has announced the addition of the " Philippines Pharmaceuticals and Healthcare Report Q1 2010 " report to their offering. Comment?
-
Lorus Therapeutics Announces Positive Result in Its Phase II Clinical ...
Inc. , a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that its Phase II clinical trial in refractory and relapsed AML with LOR-2040 in combination with cytarabine has been successfully completed to the end-of-stage assessment time ... Comment?
-
Lorus Therapeutics Announces Positive Result In Its Phase II Clinical ...
Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Clinical Trials / Drug Trials ; Blood / Hematology ; Cancer / Oncology Article Date: 01 Dec 2009 - 0:00 PST Lorus Therapeutics Inc. Comment?
-
Aegera commences Phase IIb study of AEG35156 for treatment of acute myeloid leukemia
The study, entitled "An Open-Label Randomised Phase II Study of the X-Linked Inhibitor of Apoptosis Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen", is being conducted in the United States and Canada and will also be ... Comment?
-
Aegera Therapeutics Initiates a Randomized Phase 2B Study with...
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia MONTREAL , /CNW Telbec/ - Aegera Therapeutics Inc. Comment?
-
Antisoma AGM update and Interim Management Statement
ASM ; USOTC: ATSMY) holds its AGM today and provides an update, which also serves as the Company's Interim Management Statement for the period from 1 July 2009 to 9 November 2009. Comment?
-
Antisoma AGM update and Interim Management Statement
Antisoma plc holds its AGM today and provides an update, which also serves as the Company's Interim Management Statement for the period from 1 July 2009 to 9 November 2009. Comment?
-
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new...
Fotemustine plus etoposide, cytarabine and melphalan as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study 1Department of Oncology, Oncohematology and Bone Marrow Transplantation Unit, 'La Maddalena', Palermo, Italy 2Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, ... Comment?
Cytosar-U, Cytarabine Forum
| Topic | Comments |
|---|---|
| Bone cancer treatment ineffective, de... | 1 |
| FDA Grants Full Approval for DepoCyt ... | 1 |
Most Popular
- Major Online Retailer Offers Products With Veiled Threats Against Obama - 361 comments
- Hispanics claim racial profiling by officers - 158 comments
- Senator DeMint: "Gay President Would be Immoral" - 141 comments
- Madison Central Principal, Teachers Sued Over Stabbing - 194 comments
- Hawaii abuzz about Obama's expected holiday return - 125 comments
- Now is the time for ILLEGAL immigration reform - 110 comments
- Obama Wants to Scale Back on Drone Strikes - 62 comments
- Erie's Extreme Makeover Airs Sunday on JET-TV - 74 comments
- Obama presses bank chiefs to lend more - 46 comments
- Congress: Would you please turn that TV ad down - 55 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
